SPS
AVIR icon

Susquehanna Portfolio Strategies’s Atea Pharmaceuticals AVIR Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$299K Buy
+55,487
New +$255K ﹤0.01% 841
2024
Q2 		– Sell
-80,830
Closed -$327K – 534
2024
Q1 		$327K Sell
80,830
-2,445
-3% -$9.57K 0.01% 651
2023
Q4 		$254K Buy
+83,275
New +$252K ﹤0.01% 891

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Susquehanna Portfolio Strategies's AVIR Position: Q1 2026 in Review

Susquehanna Portfolio Strategies opened a new position in Atea Pharmaceuticals (AVIR) in Q1 2026: 55,487 shares worth $299K. The stake represents ﹤0.01% of the portfolio and ranks #841 among its holdings. This is a return to the name: Susquehanna Portfolio Strategies previously reported a position in AVIR as recently as Q1 2024.

Susquehanna Portfolio Strategies first reported a position in AVIR in Q4 2023 and has held it in 3 quarters since. The position peaked at $327K in Q1 2024. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • Susquehanna Portfolio Strategies held 55,487 shares of Atea Pharmaceuticals worth $299K as of Q1 2026.
  • Atea Pharmaceuticals was a new Susquehanna Portfolio Strategies position in Q1 2026.
  • Atea Pharmaceuticals made up ﹤0.01% of Susquehanna Portfolio Strategies's portfolio in Q1 2026, its #841 holding.
  • Susquehanna Portfolio Strategies first reported a position in Atea Pharmaceuticals in Q4 2023 and has held it in 3 quarters since.
  • Susquehanna Portfolio Strategies's Atea Pharmaceuticals position peaked at $327K in Q1 2024.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q1 2026, filed 15 May 2026.